PCI The Journeys Within
Media Pack
News

Current Edition

JCS - Volume 18 Issue 3 - Autumn 2026
Frankfurt 2027 – 12/10/26
ramusmedical
Europe

AstraZeneca blood cancer drug hits study goal early

A Phase 3 trial testing AstraZeneca's Calquence in previously treated chronic lymphocytic leukemia will be stopped early, after an interim analysis found patients...
16 May 2019 Europe | news | Regional News
Continue Reading →
Europe

Bristol-Myers’ Opdivo fails in Phase 3 glioblastoma test

Bristol-Myers Squibb said a late-stage Opdivo study showed the medicine failed to prolong overall survival in patients with a type of newly diagnosed brain cancer.Th...
16 May 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Myovant reports a Phase 3 success, but Wall Street isn’t cheered

An experimental drug from Myovant Sciences met its main goal in a Phase 3 trial of women with uterine fibroids, results which keep the biotech on track to file the d...
16 May 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Pfizer, Merck KGaA’s latest Bavencio nod sets up 3-way kidney cancer battle

The FDA approved Pfizer and Merck KGaA's Bavencio in combination with Inlyta for the first-line treatment of patients with advanced kidney cancer. (Pfizer) Pfize...
16 May 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Watch out, Dupixent. Pfizer’s new JAK inhibitor could come after your eczema market

In a possible relief for Pfizer and for abrocitinib as a JAK inhibitor, fewer patients on it than on placebo stopped therapy due to side effects. (Tracy Staton) P...
16 May 2019 Europe | news | North America | Regional News
Continue Reading →
Asia Pacific

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuz...
16 May 2019 Asia Pacific | news | Regional News
Continue Reading →
news

Cytokinetics, Astellas fall short in ALS trial, but spin a success story

Cytokinetics said Sunday its experimental drug failed a Phase 2 study of patients with amyotrophic lateral sclerosis, the neurodegenerative disease known as ALS. But...
9 May 2019 news | North America | Regional News
Continue Reading →
news

Epidiolex sales beat Wall Street’s bar as GW Pharma reports trial success

GW Pharma's seizure medicine Epidiolex handily surpassed Wall Street forecasts for sales during the first quarter, and the biotech gave reason for further optimism b...
9 May 2019 news | North America | Regional News
Continue Reading →
Europe

‘Pathbreaking’ Ionis trial offers way forward in Huntington’s disease

An experimental drug developed by Ionis Pharmaceuticals and Roche could offer a way forward to treat Huntington's disease, nearly three decades after researchers ...
9 May 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

GSK chases Trelegy asthma nod with mixed phase 3 results

An approval for GSK's Trelegy in asthma patients could help the company offset the continued fall of its long-time blockbuster Advair. (GlaxoSmithKline) With gen...
9 May 2019 Europe | news | North America | Regional News
Continue Reading →
Quotient
jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte